Sanofi announced on Wednesday that Iglarlixi, the combination in fixed adjustable proportion in insulin investigation phase Glargina 100 U/ml and the agonist of the GLP-1 receiver (glucagon-likepeptide 1 [peptide similar to the type 1 glucagon]) Lixisenatida,It allows a better glycemia control after meals (postprandial glycemia, GPP) in adults suffering from type 2 diabetes compared to insulin 100 U/ml glargine in monotherapy.
The new analysis has been presented at the 52th Annual Congress of the European Association for the study of Diabetesun New Another analysis of the data of the Pivotal clinical trial in phase III Lixilan-L detected that the number of patients who achieved their desired daily valueof GPP was greater among those who had received the combination in fixed proportion than among those who had only received insulin Glargina 100 U/ml.
The new analysis was presented at the 52th Annual Congress of the European Association for the Study of Diabetes (AEED) in Munich.Iglarlixi is in the process of review in the United States and Europe.
"Blood control after meals is an important factor in maintaining global blood glucose control, which helps patients treat their diabetes," says Josep Vidal, specialist at the Clinic Hospital of Barcelona and main author of the study."This new analysis provides additional evidence that supports the use of Iglarlixi in adults with type 2 diabetes that need to control blood glucose after meals, while achieving better control of HBA1C."
"Glycemia control after meals is an important factor in maintaining global blood glucose control"
The analysis also showed that a significantly high proportion of participants achieved its desired GPP value after 30 weeks, according to the SMPG (Self-Measured Plasma Glucose, self-glucose automedition in plasma) performed at intervals throughout the day.As previously notified for Lixilan-L, the incidence of symptomatic hypoglycemia episodes was similar with the combination in adjustable fixed proportion and with insulin Glargina 100 U/mL.
"In the Pivotal clinical trial in phase III Lixilan-L, Iglarlixi, in the investigation phase, produced a greater reduction of the HBA1C compared to insulin Glargina 100 U/ml," says Riccardo Perfetti, head of the global diabetes medical team ofHealthy."Thanks to this new analysis, we have more evidence of how Iglarlixi can help patients with type 2 diabetes to achieve their desired GPP value."